| Old Articles: <Older 29441-29450 Newer> |
|---|
 |
The Motley Fool
April 2, 2008
Rick Aristotle Munarriz |
Extraordinary Yields in Extraordinary Places What if I were to tell you that you can find some surprisingly head-turning yields in unlikely areas like wrestling mats, roller coasters, and even adult films?   |
The Motley Fool
April 2, 2008
Brian Lawler |
Seattle Genetics Bulks Up Its Pipeline Seattle Genetics biopharmaceutical clinical studies are firing on all cylinders. |
The Motley Fool
April 2, 2008
Richards & Hanson |
Now Is No Time to Stop Buying Stocks If we accept downturns as a fact of investing, we'll know not to panic. |
The Motley Fool
April 2, 2008
Joe Magyer |
Stock Madness Final 4: Starbucks Which company will win the Stock Madness championship? Starbucks and Apple pair off in this match. |
Financial Planning
April 1, 2008
Steve Savage |
Backward Thinking Investors see more risk when risk is lower and less risk when it's higher. Why is this? |
The Motley Fool
April 1, 2008
Sham Gad |
The World Hates Stocks It's time to overcome your fears and start enjoying the bargains. |
The Motley Fool
April 1, 2008
Toby Shute |
Noble's Brazilian Bonanza Noble lines up a massive contract renewal on five deepwater rigs that are already in Petrobras' service. |
The Motley Fool
April 1, 2008
Brian Lawler |
BioMarin Drug Heads Overseas One of the pharmaceutical's enzyme replacement therapy drugs gets approved in Japan. |
The Motley Fool
April 1, 2008
Brian Lawler |
Vertex Proves It ... Almost Vertex announces exciting clinical trial data that could get its anti-hepatitis C virus compound onto the market years earlier. |
The Motley Fool
April 1, 2008
Brian Lawler |
Cephalon Plays "Let's Make a Deal" Cephalon acquires an oncology drug on the cheap from tiny Acusphere. |
| <Older 29441-29450 Newer> Return to current articles. |
